The Rapid Emergence of Novel Therapeutics in Advanced Malignant Melanoma.

Dermatol Ther (Heidelb) · 2015 · PMC4580658 · PMID 26387031

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

An update presented at ESMO 2014 showed a median OS of 20 and 15.6 months for the dabrafenib arm and dacarbazine arm, respectively, but did not reach statistical significance (HR 0.77 with 95% CI 0.52–1.13) [ 14 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.